rs397508463
Positions:
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 9P and 0B. PM1PM2PP3_StrongPP5
The NM_000492.4(CFTR):c.2939T>A(p.Ile980Lys) variant causes a missense change. The variant allele was found at a frequency of 0.0000113 in 1,593,778 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.000026 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0000097 ( 0 hom. )
Consequence
CFTR
NM_000492.4 missense
NM_000492.4 missense
Scores
8
8
3
Clinical Significance
Conservation
PhyloP100: 4.46
Genes affected
CFTR (HGNC:1884): (CF transmembrane conductance regulator) This gene encodes a member of the ATP-binding cassette (ABC) transporter superfamily. The encoded protein functions as a chloride channel, making it unique among members of this protein family, and controls ion and water secretion and absorption in epithelial tissues. Channel activation is mediated by cycles of regulatory domain phosphorylation, ATP-binding by the nucleotide-binding domains, and ATP hydrolysis. Mutations in this gene cause cystic fibrosis, the most common lethal genetic disorder in populations of Northern European descent. The most frequently occurring mutation in cystic fibrosis, DeltaF508, results in impaired folding and trafficking of the encoded protein. Multiple pseudogenes have been identified in the human genome. [provided by RefSeq, Aug 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
PM1
In a topological_domain Cytoplasmic (size 50) in uniprot entity CFTR_HUMAN there are 8 pathogenic changes around while only 1 benign (89%) in NM_000492.4
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.982
PP5
Variant 7-117606704-T-A is Pathogenic according to our data. Variant chr7-117606704-T-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 53604.We mark this variant Likely_pathogenic, oryginal submissions are: {Likely_pathogenic=2, not_provided=1, Uncertain_significance=2, Pathogenic=3}.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.2939T>A | p.Ile980Lys | missense_variant | 18/27 | ENST00000003084.11 | NP_000483.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CFTR | ENST00000003084.11 | c.2939T>A | p.Ile980Lys | missense_variant | 18/27 | 1 | NM_000492.4 | ENSP00000003084 | P2 | |
ENST00000456270.1 | n.178-1715A>T | intron_variant, non_coding_transcript_variant | 3 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152202Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
4
AN:
152202
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000796 AC: 2AN: 251150Hom.: 0 AF XY: 0.00000737 AC XY: 1AN XY: 135770
GnomAD3 exomes
AF:
AC:
2
AN:
251150
Hom.:
AF XY:
AC XY:
1
AN XY:
135770
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000971 AC: 14AN: 1441576Hom.: 0 Cov.: 26 AF XY: 0.00000835 AC XY: 6AN XY: 718722
GnomAD4 exome
AF:
AC:
14
AN:
1441576
Hom.:
Cov.:
26
AF XY:
AC XY:
6
AN XY:
718722
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152202Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74364
GnomAD4 genome
AF:
AC:
4
AN:
152202
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
74364
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
2
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:5Uncertain:2Other:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Cystic fibrosis Pathogenic:2Uncertain:1Other:1
not provided, no classification provided | literature only | ClinVar Staff, National Center for Biotechnology Information (NCBI) | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Dec 14, 2017 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 27, 2023 | The p.I980K variant (also known as c.2939T>A), located in coding exon 18 of the CFTR gene, results from a T to A substitution at nucleotide position 2939. The isoleucine at codon 980 is replaced by lysine, an amino acid with dissimilar properties. This variant was reported in two individuals, who also had another pathogenic mutation, with congenital bilateral absence of the vas deferens (CBAVD). One individual also had an elevated sweat chloride concentration and presented with chronic sinusitis, nasal polyposis and pancreatic sufficiency (Bienvenu et al. Hum Mutat. 1996;7:182). In another study, this variant was seen in two patients in a cohort of 305 with CBAVD, of which one individual also had p.R117H and the other individual had c.3605delA, however further clinical information was not provided (Steiner et al. Hum Mutat. 2011;32:912-20). In a group of 110 patients who were diagnosed with cystic fibrosis by two abnormal sweat chloride levels and/or two CFTR mutations, one was reported with this variant (Hubert et al. Eur. Respir. J. 1996;9(11):2207-14). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 10, 2023 | This sequence change replaces isoleucine, which is neutral and non-polar, with lysine, which is basic and polar, at codon 980 of the CFTR protein (p.Ile980Lys). This variant is present in population databases (rs397508463, gnomAD 0.003%). This missense change has been observed in individual(s) with congenital absence of the vas deferens and/or cystic fibrosis (PMID: 8829643, 8947061, 11101688, 21520337). ClinVar contains an entry for this variant (Variation ID: 53604). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CFTR protein function with a positive predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Nov 19, 2021 | - - |
CFTR-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | curation | CFTR-France | Jan 29, 2018 | - - |
Congenital bilateral aplasia of vas deferens from CFTR mutation Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 02, 2024 | Variant summary: CFTR c.2939T>A (p.Ile980Lys) results in a non-conservative amino acid change located in the ABC transporter type 1, transmembrane domain (IPR011527) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 7.9e-06 in 251838 control chromosomes. c.2939T>A has been reported in the literature in the presumed compound heterozygous or compound heterozygous state in multiple individuals affected with clinical features of Congenital Bilateral Absence Of The Vas Deferens and/or Cystic Fibrosis and/or CFTR-related disorders (example, Bienvenu_1997, Claustres_2000, Hubert_1996, Jezequel_2000, Steiner_2011). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect resulted in approximately 13.43% of normal chloride channel conductance relative to wild type (e.g., Bihler_2024). The following publications have been ascertained in the context of this evaluation (PMID: 8829643, 10923036, 20059485, 9272157, 8947061, 11101688, 21520337, 38388235). ClinVar contains an entry for this variant (Variation ID: 53604). Based on the evidence outlined above, the variant was classified as pathogenic. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Apr 17, 2019 | The CFTR c.2939T>A; p.Ile980Lys variant (rs397508463) is reported in the literature in multiple individuals affected with congenital absence of the vas deferens (CBAVD) or cystic fibrosis (CF) (Bienvenu 1996, Hubert 1996, Jezequel 2000, Steiner 2011). In all affected individuals carrying this variant, a second pathogenic variant was also identified (Bienvenu 1996, Hubert 1996, Jezequel 2000, Steiner 2011). The p.Ile980Lys variant is present on only two chromosomes (2/251150 alleles) in the Genome Aggregation Database, indicating it is not a common polymorphism. The isoleucine at codon 980 is moderately conserved, but computational analyses (SIFT: damaging, PolyPhen-2: benign) predict conflicting effects of this variant on protein structure/function. Despite its prevalence in affected individuals, due to limited information, the significance of the p.Ile980Lys variant is uncertain at this time. References: Bienvenu T et al. A novel missense mutation in exon 16 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene identified in CBAVD patients. Hum Mutat. 1996;7(2):182. Hubert D et al. Genotype-phenotype relationships in a cohort of adult cystic fibrosis patients. Eur Respir J. 1996 Nov;9(11):2207-14. Jezequel P et al. Molecular screening of the CFTR gene in men with anomalies of the vas deferens: identification of three novel mutations. Mol Hum Reprod. 2000 Dec;6(12):1063-7. Steiner B et al. Common CFTR haplotypes and susceptibility to chronic pancreatitis and congenital bilateral absence of the vas deferens. Hum Mutat. 2011 Aug;32(8):912-20. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Benign
DANN
Benign
DEOGEN2
Pathogenic
D;.;.;D;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Pathogenic
M;.;.;.;.
MutationTaster
Benign
D;D
PrimateAI
Benign
T
PROVEAN
Uncertain
D;.;.;D;.
REVEL
Pathogenic
Sift
Uncertain
D;.;.;D;.
Sift4G
Uncertain
D;.;.;D;.
Polyphen
B;.;.;.;.
Vest4
MutPred
Gain of ubiquitination at I980 (P = 0.023);.;.;.;.;
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at